LGD-4033 and Rapamycin Interaction
LGD-4033 and Rapamycin have an interaction requiring monitoring for interaction with 47% confidence. Both LGD-4033 and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. These compounds primarily affect different organ systems.
Compound Profiles
LGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
View full profileRapamycin
mTOR Inhibitor | Longevity & Immunosuppression
Rapamycin exerts its effects by binding to the intracellular protein FKBP12, forming a complex that directly and specifically inhibits mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 is a master nutrient-sensing kinase that integrates signals from growth factors, amino acids, energy status, and stress to regulate cell growth, proliferation, and metabolism.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take LGD-4033 with Rapamycin?
Yes, but with caution. Both LGD-4033 and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. Regular monitoring is advised.
Is LGD-4033 and Rapamycin safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: lipid disrupting, teratogenic. Monitor accordingly.
What are the interactions between LGD-4033 and Rapamycin?
Both LGD-4033 and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time LGD-4033 and Rapamycin?
LGD-4033 has a half-life of ~24-36 hours and Rapamycin has a half-life of ~62 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.